Boston Scientific cuts 2026 outlook after WATCHMAN and other units weaken; INTERA 3000 pump recall closed
AI Market Summary
Boston Scientific cut its 2026 full-year guidance, citing weaker-than-expected performance in WATCHMAN, Electrophysiology, and Urology, marking a meaningful near-term earnings reset. A completed Class II recall of a single INTERA 3000 hepatic artery infusion pump appears operationally immaterial, but adds incremental quality-control scrutiny. The combined update pressures the near-term growth narrative and raises execution-risk focus ahead of anticipated 2027–2028 product launches.
Impact level
● Medium
Affected assets
NCSKBSX2USD/USDT+0.02%
AI Insight · NCSKBSX2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Boston Scientific (BSX) said in July 2026 that it lowered its full-year 2026 guidance after results in WATCHMAN, Electrophysiology and Urology came in weaker than expected. Around the same period, the company completed a U.S. voluntary recall of one INTERA 3000 hepatic artery infusion pump (Serial Number 20175), a Class II action that has been closed. Management reiterated that product launches planned for 2027–2028 could support growth, but the guidance cut—its first in nearly a year—prompted investors to reassess near-term execution risk.
